Adrien Mithalal

keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US.

Les Nouvelles Éditions Indépendantes SASU operates as a holding company, with interest in newspaper publishing. The company was founded on July 27, 2009 and is headquartered in Paris, France.

DIAFIR SAS designs and develops biological testing system that provides an alternative to biopsies. Its diagnostic device uses a patented infrared sensor to identify healthy or diseased tissue by simple contact. The company was founded by Hugues Tariel, Jacques Lucas, Joel Renault, Catherine Boussard, Bruno Bureau, and Olivier Loréal in June 2011 and is headquartered in Rennes, France.

Hollister, Inc. develops, manufactures and markets healthcare products and services. Its products include Ostomy, continence, wound, skin and critical care products. The company was founded by John Dickinson Schneider in 1921 and is headquartered in Libertyville, IL.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Part of ResMed, Inc., ResMed Medizintechnik GmbH is a medical device manufacturer. The company is based in Gremsdorf, Germany. The German company was founded in 1993. The CEO is Anne Reiser.

Rythm SAS develops a device which helps to monitor and analyze the sleep. Its product, Dreem, is a sleep solution that monitors, analyzes, and acts on brain to enhance sleep. The company was founded by Hugo Mercier and Quentin Soulet de Brugière in 2014 and is headquartered in Paris, France.

Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA.

Mérieux Equity Partners SAS (Mérieux Equity Partners or MxEP) is a Private Equity and Venture Capital firm, a subsidiary of Mérieux Développement SASU founded in 2009. The firm is headquartered in Lyon, France, with additional offices across the country.

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

VALKEE Oy develops and manufactures health devices. Its flagship product Valkee is a pocket-sized light therapy device that channels bright light via the ear canals into the brain that has beneficial effects on mood and wellbeing of people. The firm is carrying out additional tests and studies concerning the effects of bright light on cognitive and physical performance and jet lag. The company was founded by Juuso Samuel Nissilä and Antti Aunio in 2007 and is headquartered in Oulu, Finland.

Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France.

Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation.

Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France.

Echosens SA engages in the manufacture of medical imaging equipment. It focuses on developing FibroScan. The company was founded by Laurent Sandrin and Sylvain Yon on June 20, 2001 and is headquartered in Paris, France.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France.

Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France.